Shopping Cart 0
Cart Subtotal
USD 0

Neurocrine Biosciences Inc (NBIX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Neurocrine Biosciences Inc (Neurocrine) discovers, develops and commercializes pharmaceutical products for the treatment of neurologic, psychiatric and endocrine related diseases and disorders. Its lead product, Ingrezza (valbenazine) capsule is a US FDA approved selective vesicular monoamine transporter 2 inhibitor for the treatment of adults with tardive dyskinesia (TD). Its other major pipeline products include elagolix, a gonadotropin-releasing hormone (GnRH) antagonist for the treatment of endometriosis and uterine fibroids and opicapone, a catechol-O-methyltransferase inhibitor (COMT inhibitor) intended for adult patients with Parkinson's disease. It also develops drug candidates for the treatment of essential tremor and classic congenital adrenal hyperplasia. The company has development and licencing partnerships with AbbVie Inc, BIAL-Portela & CA, S.A. and Mitsubishi Tanabe Pharma. Neurocrine is headquartered in San Diego, California, the US.

Neurocrine Biosciences Inc (NBIX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deal Details 10

Partnerships 10

Neurocrine Biosciences and Jnana Therapeutics Enter into Agreement 10

Licensing Agreements 11

Neurocrine Biosciences Enters into Licensing Agreement with Bial 11

Neurocrine Biosciences Enters into Licensing Agreement with Mitsubishi Tanabe Pharma 12

Equity Offering 13

Neurocrine Biosciences Raises USD288 Million in Public Offering of Shares 13

Neurocrine Biosciences Completes Public Offering Of Shares For USD 142 Million 15

Neurocrine Biosciences Completes Over-allotment Option Of Underwritten Public Offering For USD 88.5 Million 16

Debt Offering 18

Neurocrine Biosciences Raises USD517.5 Million in Private Placement of 2.25% Notes Due 2024 18

Neurocrine Biosciences Inc-Key Competitors 20

Neurocrine Biosciences Inc-Key Employees 21

Neurocrine Biosciences Inc-Locations And Subsidiaries 22

Head Office 22

Other Locations & Subsidiaries 22

Recent Developments 23

Financial Announcements 23

Nov 05, 2018: Neurocrine Biosciences reports third quarter 2018 financial results 23

Jul 31, 2018: Neurocrine Biosciences Reports Second Quarter 2018 Financial Results 27

Apr 30, 2018: Neurocrine Biosciences Announces First Quarter 2018 Financial Results 29

Feb 13, 2018: Neurocrine Biosciences Reports Fourth Quarter and Year-End 2017 Financial Results and Provides Investor Update for 2018 31

Jan 07, 2018: Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2017 Sales Results and 2018 Program Milestones 32

Nov 01, 2017: Neurocrine Biosciences Reports Third Quarter 2017 Results 33

Aug 03, 2017: Neurocrine Biosciences Reports Second Quarter 2017 Results 35

May 09, 2017: Neurocrine Biosciences Reports First Quarter 2017 Results 37

Feb 14, 2017: Neurocrine Biosciences Reports Year-End 2016 Results and Provides Investor Update for 2017 40

Corporate Communications 43

Jan 07, 2018: Neurocrine Biosciences Announces Retirement of Christopher O'Brien, M.D., and Appointment of Eiry W. Roberts, M.D., as Chief Medical Officer 43

Nov 20, 2017: Neurocrine Biosciences Appoints Matt Abernethy as Chief Financial Officer 44

Jan 06, 2017: Neurocrine Biosciences Announces the Appointment of David-Alexandre Gros M.D. President and Chief Operating Officer 45

Appendix 46

Methodology 46

About GlobalData 46

Contact Us 46

Disclaimer 46


List Of Figure

List of Figures

Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Neurocrine Biosciences Inc, Deals By Therapy Area, 2012 to YTD 2018 8

Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Neurocrine Biosciences and Jnana Therapeutics Enter into Agreement 10

Neurocrine Biosciences Enters into Licensing Agreement with Bial 11

Neurocrine Biosciences Enters into Licensing Agreement with Mitsubishi Tanabe Pharma 12

Neurocrine Biosciences Raises USD288 Million in Public Offering of Shares 13

Neurocrine Biosciences Completes Public Offering Of Shares For USD 142 Million 15

Neurocrine Biosciences Completes Over-allotment Option Of Underwritten Public Offering For USD 88.5 Million 16

Neurocrine Biosciences Raises USD517.5 Million in Private Placement of 2.25% Notes Due 2024 18

Neurocrine Biosciences Inc, Key Competitors 20

Neurocrine Biosciences Inc, Key Employees 21

Neurocrine Biosciences Inc, Subsidiaries 22

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Neurocrine Biosciences Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Neurocrine Biosciences Inc (Neurocrine) discovers, develops and commercializes pharmaceutical products for the treatment of neurologic, psychiatric and endocrine related diseases and disorders. Its lead product, Ingrezza (valbenazine) capsule is a US FDA approved selective vesicular monoamine transporter 2 inhibitor for the treatment of adults with tardive dyskinesia (TD). Its other major pipeline products include elagolix, a gonadotropin-releasing hormone (GnRH) antagonist for the treatment of endometriosis and uterine fibroids and opicapone, a catechol-O-methyltransferase inhibitor (COMT inhibitor) intended for adult patients with Parkinson's disease. It also develops drug candidates for the treatment of essential tremor and classic congenital adrenal hyperplasia. The company has development and licencing partnerships with AbbVie Inc, BIAL-Portela & CA, S.A. and Mitsubishi Tanabe Pharma. Neurocrine is headquartered in San Diego, California, the US.

Neurocrine Biosciences Inc (NBIX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deal Details 10

Partnerships 10

Neurocrine Biosciences and Jnana Therapeutics Enter into Agreement 10

Licensing Agreements 11

Neurocrine Biosciences Enters into Licensing Agreement with Bial 11

Neurocrine Biosciences Enters into Licensing Agreement with Mitsubishi Tanabe Pharma 12

Equity Offering 13

Neurocrine Biosciences Raises USD288 Million in Public Offering of Shares 13

Neurocrine Biosciences Completes Public Offering Of Shares For USD 142 Million 15

Neurocrine Biosciences Completes Over-allotment Option Of Underwritten Public Offering For USD 88.5 Million 16

Debt Offering 18

Neurocrine Biosciences Raises USD517.5 Million in Private Placement of 2.25% Notes Due 2024 18

Neurocrine Biosciences Inc-Key Competitors 20

Neurocrine Biosciences Inc-Key Employees 21

Neurocrine Biosciences Inc-Locations And Subsidiaries 22

Head Office 22

Other Locations & Subsidiaries 22

Recent Developments 23

Financial Announcements 23

Nov 05, 2018: Neurocrine Biosciences reports third quarter 2018 financial results 23

Jul 31, 2018: Neurocrine Biosciences Reports Second Quarter 2018 Financial Results 27

Apr 30, 2018: Neurocrine Biosciences Announces First Quarter 2018 Financial Results 29

Feb 13, 2018: Neurocrine Biosciences Reports Fourth Quarter and Year-End 2017 Financial Results and Provides Investor Update for 2018 31

Jan 07, 2018: Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2017 Sales Results and 2018 Program Milestones 32

Nov 01, 2017: Neurocrine Biosciences Reports Third Quarter 2017 Results 33

Aug 03, 2017: Neurocrine Biosciences Reports Second Quarter 2017 Results 35

May 09, 2017: Neurocrine Biosciences Reports First Quarter 2017 Results 37

Feb 14, 2017: Neurocrine Biosciences Reports Year-End 2016 Results and Provides Investor Update for 2017 40

Corporate Communications 43

Jan 07, 2018: Neurocrine Biosciences Announces Retirement of Christopher O'Brien, M.D., and Appointment of Eiry W. Roberts, M.D., as Chief Medical Officer 43

Nov 20, 2017: Neurocrine Biosciences Appoints Matt Abernethy as Chief Financial Officer 44

Jan 06, 2017: Neurocrine Biosciences Announces the Appointment of David-Alexandre Gros M.D. President and Chief Operating Officer 45

Appendix 46

Methodology 46

About GlobalData 46

Contact Us 46

Disclaimer 46


List Of Figure

List of Figures

Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Neurocrine Biosciences Inc, Deals By Therapy Area, 2012 to YTD 2018 8

Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Neurocrine Biosciences and Jnana Therapeutics Enter into Agreement 10

Neurocrine Biosciences Enters into Licensing Agreement with Bial 11

Neurocrine Biosciences Enters into Licensing Agreement with Mitsubishi Tanabe Pharma 12

Neurocrine Biosciences Raises USD288 Million in Public Offering of Shares 13

Neurocrine Biosciences Completes Public Offering Of Shares For USD 142 Million 15

Neurocrine Biosciences Completes Over-allotment Option Of Underwritten Public Offering For USD 88.5 Million 16

Neurocrine Biosciences Raises USD517.5 Million in Private Placement of 2.25% Notes Due 2024 18

Neurocrine Biosciences Inc, Key Competitors 20

Neurocrine Biosciences Inc, Key Employees 21

Neurocrine Biosciences Inc, Subsidiaries 22

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Neurocrine Biosciences Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.